Piperidine → N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(piperidin-1-yl)-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine
反応式
Cl[C:2]1[N:7]=[C:6]([NH:8][C:9]2[CH:13]=[C:12]([CH:14]3[CH2:16][CH2:15]3)[NH:11][N:10]=2)[C:5]([C:17]#[C:18][Si:19]([CH3:22])([CH3:21])[CH3:20])=[CH:4][N:3]=1.[NH:23]1[CH2:28][CH2:27][CH2:26][CH2:25][CH2:24]1>CC(O)C>[CH:14]1([C:12]2[NH:11][N:10]=[C:9]([NH:8][C:6]3[C:5]([C:17]#[C:18][Si:19]([CH3:22])([CH3:21])[CH3:20])=[CH:4][N:3]=[C:2]([N:23]4[CH2:28][CH2:27][CH2:26][CH2:25][CH2:24]4)[N:7]=3)[CH:13]=2)[CH2:16][CH2:15]1参加物
4
実験手順
A mixture of 2-chloro-N-(5-cyclopropyl-1H-pyrazol-3-yl)-5-((trimethylsilyl)ethynyl) pyrimidin-4-amine (200 mg, 0.6 mmol, 1.0 eq), piperidine (102.7 mg, 1.2 mmol, 2.0 eq) in iPrOH (4 ml) was stirred at room temperature for 2 h. Then the mixture was washed with water, extracted with EtOAc, dried (Na2SO4). EtOAc was removed by evaporation and the residue was recrystalized by PE to give compound N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(piperidin-1-yl)-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine (101 mg, 44.3%).